> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Ligand Lifts 2026 Adjusted EPS Forecast To $9.50-$9.75 As XOMA Royalties Jump 51%
- URL: https://www.bullished.co/ligand-lifts-2026-adjusted-eps-forecast-to-9-50-9-75-as-xoma-royalties-jump-51-84dcb484/
- Published: 2026-10-29T11:26:18.000Z
- Updated: 2026-10-29T11:26:18.000Z
- Description: Royalty revenue rose to $70.3 million in the third quarter, while non-cash investment markdowns pushed Ligand to a $28.5 million net loss.
- Author: Matteo Parrino
- Tags: Earnings, LGND, Industry: Healthcare

Ligand Pharmaceuticals, which buys and structures royalty interests in medicines developed by other drug companies, raised its 2026 adjusted earnings forecast to $9.50 to $9.75 per diluted share, from $9.00 to $9.50, after third-quarter [royalty revenue climbed 51% to $70.3 million](https://www.sec.gov/Archives/edgar/data/0000886163/000088616326000058/lgnd-20261029.htm?ref=bullished.co), the company said Thursday. A non-cash markdown on investments still left it with a GAAP net loss.

## Royalties up, total revenue down

Royalty revenue was $70.3 million against $46.6 million a year earlier, and royalties made up 89% of total revenues and income, [the company reported](https://www.sec.gov/Archives/edgar/data/0000886163/000088616326000058/q32026earningsrelease%5Fex991.htm?ref=bullished.co). Ligand credited the newly acquired XOMA assets and its key commercial royalties, including Travere Therapeutics' Filspari and Merck's Ohtuvayre.

Total revenues and income fell 32% to [$78.7 million](https://www.globenewswire.com/news-release/2026/10/29/3391098/0/en/ligand-reports-third-quarter-2026-financial-results.html?ref=bullished.co) from $115.5 million. The year-ago quarter held $53.1 million of income tied to the divestiture of Pelthos; excluding it, the total rose 26%.

Revenue guidance of $270 million to $310 million was reaffirmed, with royalty revenue guided to $225 million to $250 million.

## A $28.5 million loss, mostly markdowns

The GAAP net loss was $28.5 million, or $1.43 per share, against net income of $117.3 million a year earlier. The quarter included $39.5 million of pre-tax losses, among them a $35.7 million non-cash loss from changes in the fair value of equity-method and other investments.

Adjusted earnings were $2.67 per diluted share, down from $3.09\. Ligand pointed to the prior-year Pelthos out-license income and higher general and administrative costs, partly offset by royalty growth.

Those costs reached [$72.6 million](https://www.globenewswire.com/news-release/2026/10/29/3391098/0/en/ligand-reports-third-quarter-2026-financial-results.html?ref=bullished.co), from $28.4 million, on transaction, integration and stock compensation tied to the XOMA deal, plus added staff.

## XOMA doubles the portfolio

Ligand completed its purchase of XOMA Royalty on July 14\. It added seven commercial products, including Roche's Vabysmo, and 14 late-stage programs, and the portfolio now totals more than 200 assets, the company said.

Cash and short-term investments fell to $447.4 million from $733.5 million at the end of 2025, mainly from paying for XOMA, partly offset by convertible notes due 2031\. Ligand says it has about $750 million of deployable capital, counting equity investments and its credit facility.

In September it paid $23 million upfront for a royalty interest in Santen's Ryjunea and committed up to $41 million to AvenCell Therapeutics for a royalty on its pipeline.

Ligand will present an updated five-year outlook at its investor day on December 8, and the FDA's target decision date for Palvella's Qtorin rapamycin application is February 28, 2027.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — LIGAND PHARMACEUTICALS INC (LGND)](https://www.sec.gov/Archives/edgar/data/0000886163/000088616326000058/lgnd-20261029.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit q32026earningsrelease\_ex991.htm — LIGAND PHARMACEUTICALS INC 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000886163/000088616326000058/q32026earningsrelease%5Fex991.htm?ref=bullished.co) — SEC EDGAR
- [Ligand Reports Third Quarter 2026 Financial Results](https://www.globenewswire.com/news-release/2026/10/29/3391098/0/en/ligand-reports-third-quarter-2026-financial-results.html?ref=bullished.co) — globenewswire.com